Research & Innovation
Radiation Therapy
BP-C2 Applications
BP-C2 is being explored to enhance radiation therapy, reducing side effects and improving patient recovery. It protects healthy tissue from radiation damage, reducing toxicity while maintaining treatment efficacy.
Clinical studies suggest that BP-C2 plays a crucial role in safeguarding normal tissues during radiation exposure. By accelerating DNA repair mechanisms, BP-C2 minimizes long-term damage and improves patient outcomes. BP-C2 functions as a radioprotective agent by stabilizing cellular structures and enhancing the repair of radiation-induced DNA strand breaks, a key factor in mitigating oncogenic transformation.
Research has demonstrated its ability to modulate oxidative stress responses, thereby reducing inflammation and cellular apoptosis in healthy tissues. Additionally, BP-C2 may influence cellular metabolic pathways, optimizing tissue resilience against ionizing radiation. Its potential applications include reducing toxicity in vital organs, limiting fibrosis formation, and enhancing post-treatment recovery in cancer patients undergoing radiotherapy.
Ongoing preclinical and clinical studies continue to investigate its mechanisms of action and long-term safety profile, further positioning BP-C2 as a promising adjunct in radiation oncology.
Oncology Research
BP-C1 in Cancer Treatment
BP-C1 is a novel platinum-based chemotherapy for metastatic cancer treatment, including breast and pancreatic cancers. Its unique formulation offers reduced toxicity and improved patient compliance.
BP-C1 is an advanced platinum-based chemotherapeutic agent engineered to offer superior efficacy with a reduced toxicity profile compared to conventional platinum drugs such as cisplatin and carboplatin.
Unlike traditional chemotherapies, BP-C1 is formulated for intramuscular administration, allowing for a more controlled release and improved bioavailability. Studies indicate that BP-C1 selectively targets tumor cells while minimizing damage to healthy tissues by modulating DNA cross-linking mechanisms that induce apoptosis in malignant cells.
Preclinical and clinical investigations have demonstrated its potential in treating metastatic cancers, particularly breast and pancreatic cancers, where resistance to standard therapies presents a significant challenge.
Furthermore, BP-C1 exhibits immunomodulatory properties, contributing to a more favorable tumor microenvironment by reducing inflammation and enhancing immune surveillance.
Current research is focused on elucidating its precise molecular interactions, optimizing dosage regimens, and expanding its applications across additional oncological indications. BP-C1 represents a new frontier in chemotherapy, offering a promising solution for patients who require effective yet less toxic cancer treatments.
Space
BP-C2 in Space Research
BP-C2 supports DNA repair and radiation protection, offering potential applications in space medicine. It could help safeguard astronauts from cosmic radiation during long-duration space missions.
BP-C2 plays a critical role in mitigating the biological effects of space radiation, which presents one of the greatest challenges for long-duration human spaceflight. Exposure to galactic cosmic rays (GCRs) and solar particle events (SPEs) induces DNA damage, oxidative stress, and cellular senescence, increasing the risk of carcinogenesis, neurodegeneration, and cardiovascular diseases among astronauts. BP-C2 functions as a radioprotective agent by enhancing DNA repair pathways, modulating oxidative stress responses, and stabilizing cellular homeostasis under extreme space conditions.
Studies suggest that BP-C2 enhances nucleotide excision repair (NER) and homologous recombination (HR), two key mechanisms involved in the repair of complex double-strand breaks caused by high-energy ionizing radiation. Furthermore, BP-C2 exhibits strong antioxidant properties, reducing the accumulation of reactive oxygen species (ROS) that contribute to long-term radiation-induced tissue damage. Research has also indicated that BP-C2 may support mitochondrial function, improving energy metabolism and cellular resilience under microgravity conditions.
BP-C2’s potential applications extend beyond astronaut health protection, with implications for radiation countermeasures on Earth, including medical treatments for individuals undergoing radiotherapy and nuclear industry workers exposed to ionizing radiation. Ongoing investigations are focused on validating its efficacy in space-like radiation environments through ground-based simulations and potential future trials on the International Space Station (ISS) and deep-space missions.
BP-C2 represents a promising innovation in space medicine, offering a targeted approach to safeguarding human health during long-duration missions beyond Earth’s protective magnetic field.
BP‑C3 –
Oral (Aging support & supportive care).
BP-C3 is an oral, science-backed therapeutic designed to support healthy aging, vitality, and systemic resilience in both cancer patients and aging populations.
Developed by RDI using the proprietary BP-Cx1 polyphenolic platform, BP-C3 addresses core mechanisms of aging and treatment-related fatigue — making it a powerful tool in both oncology support and the broader longevity market.
Fab4Future
A Biofabrication Toolbox for Sustainable Living Materials
Fab4Future is an interdisciplinary research initiative focused on developing a biofabrication toolbox for the next generation of sustainable living materials in the life sciences. The project integrates advanced fabrication methods and AI-driven technologies to enable tailored and scalable production of functional biomaterials.
Fab4Future explores biofabrication technologies with applications in regenerative medicine, sustainable food production, and biomaterials engineering. Unlike conventional approaches, Fab4Future focuses on:
- 3D bioprinting and tissue engineering to create realistic, lab-grown models for medical research.
- Cultivated meat production, developing food alternatives that mimic traditional meat in taste, texture, and nutritional value.
- Sustainable material innovations, leveraging biofabrication to create environmentally friendly products.
The project unites expertise across synthetic biology, biomaterials science, and AI-driven bioengineering, paving the way for scalable, sustainable solutions in medicine and food production.
PULSE Project
Bioprinting for Space Research and Medicine
PULSE is an EU-funded research initiative dedicated to advancing bioprinting technology using magnetic and acoustic levitation. The project focuses on creating precise 3D heart models to study how space conditions and radiation affect cardiovascular health. This research aims to improve human health both on Earth and in space by enhancing our understanding of cardiovascular physiology and pathology.
The PULSE Project pioneers scaffold-free bioprinting to develop realistic, functional heart tissue models. Unlike traditional 3D bioprinting techniques, PULSE employs magnetic and acoustic levitation to assemble biological structures with enhanced precision. Key research areas include:
- Cardiovascular Research in Space: Investigating how microgravity and space radiation impact heart function at the cellular and tissue levels.
- Innovative Bioprinting Technology: Developing new techniques to create highly accurate 3D tissue models for medical research.
- Applications for Earth-Based Medicine: Advancing regenerative medicine, drug testing, and precision diagnostics using bioprinted cardiac tissues.
- Collaboration with Space Agencies & Research Institutions: Partnering with ESA and other international organizations to integrate bioprinted heart models into space research.
This project unites experts across bioprinting, space medicine, biophysics, and computational biology to push the boundaries of next-generation medical technology.